miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
New MRG-106 Phase 1 cutaneous T-cell lymphoma clinical trial data released Expansion of the MRG-106 trial to include additional potential indications Two new independent members added to its Board of Directors Conference call and webcast today at 4:30 p.m. …